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Investigational New Drugs
The Journal of New Anticancer Agents
Editor-in-Chief, Eric K. Rowinsky
Attn: Laura.Walsh laura.walsh@springer.com
Ann Salvador anna.salvador@springer.com
Re: A short report on article by V. Pruliere-Escabasse et al.,
Vol. 27: 285–286, 2009
Dear Editor,
I have recently read the article on “Rhinitis and epistaxis in
patients treated with antiangiogenic therapy.” It a k ee x c e p -
tion to their conclusion. I have used bevacizumab, a VEGF
inhibitor successfully in patients with HHT epistaxis. In the
first report [1] the bevacizumab was injected and in the
second report [2] the bevacizumab was sprayed. In both
applications the bevacizumab was used in low concentrations
namely 50–100 mgs and not in cancer doses such as 5–
10 mgs per kilograms IV q 2 weeks.
In both papers we report resolution of HHT related
epistaxis. In no cases did we see crusting or atrophic
rhinitis. I strongly suspect that whatever nasal changes were
seen, may or may not be related to the patient’s disease or
the therapy, but if indeed it was, I would be more suspect
about the combination chemotherapy then I would about
the VEGF inhibitors. As VEGF inhibitors play an important
role in the treatment of a number of nasal conditions, this
report of an adverse event must be taken with great caution.
Sincerely,
Terence M. Davidson, M.D., FACS
Professor of Surgery
Division of Otolaryngology-Head and Neck Surgery
Associate Dean for UCSD Continuing Medical Education
Section Chief, VA Head and Neck Surgery
TMD:bas
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Investigational New Drugs
Dear Editor
We thank Dr Terence M Davidson for his interest
concerning our recent letter published in Investigational
new drugs which reported « atrophic rhinitis » in patients
treated with antiangiogenic therapies.
Dr Terence Davidson reported in the correspondance that
patients with HHT treated with local or systemic low dose
of bevaczumab do not present any « atrophic rhinitis ».
First of all, our patients were treated with standard dose
of antiangiogenic therapies (VEGFR inhibitors or VEGF
inhibitors). Secondly, all our patients were treated with
systemic therapies and not with local application. Finally, 2
patients were only treated with VEGFR inhibitor (without
any chemotherapy) and also presented the same « atrophic
rhinitis ».
We think that this observation is very interesting, but our
experience (with more than 30 patients prospectively
followed-up)clearly shows that patients treated with anti-
cancer doses of VEGFR or VEGF inhibitors usually develop
very particular rhinitis.
Christophe Massard, Virginie Escabasse, Jean-Charles
Soria
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